01—Abstract
Summary
Summary of the 8-K filed September 5, 2024. Cited figures are marked; the original filing is the authoritative source.
Cencora, Inc. (COR) filed an 8-K on September 5, 2024, to update investors on recent business developments and performance expectations.
The company has raised its full fiscal year 2024 adjusted diluted EPS guidance to a range of $13.60 to $13.70a, reflecting strong ongoing results. This upward revision signals positive momentum for the current fiscal year. Looking ahead to fiscal year 2025, Cencora anticipates adjusted operating income and adjusted diluted EPS growth to be at the lower end of their long-term target ranges (5-8% and 8-12%, respectively).
This is primarily attributed to headwinds from COVID-related products, including commercial vaccines and the phasing out of a prior exclusive COVID therapy contribution. Additionally, a potential June 2025 loss of an oncology customer due to an acquisition will moderately impact these expectations. On a positive note, the company has secured an important contract extension, extending its pharmaceutical supply agreement with Evernorth Health Services (formerly Express Scripts) by three years through September 2029.
02—Key points
Key Highlights
- FY2024 adjusted diluted EPS guidance increased to $13.60 - $13.70.
- FY2025 adjusted operating income and EPS growth expected at the bottom end of long-term targets (5-8% and 8-12%).
- Headwinds for FY2025 include decreased COVID product demand (vaccines) and prior year COVID therapy contributions.
- Potential loss of an oncology customer in June 2025 due to acquisition is a minor factor for FY2025 outlook.
- Pharmaceutical supply agreement with Evernorth Health Services extended for three additional years through September 2029.
- Company executives will present at multiple upcoming healthcare conferences, offering further insights.
- The filing serves as a Regulation FD disclosure, providing material non-public information concurrently to all investors.
03—Questions
Frequently Asked Questions
Why did Cencora raise its FY2024 EPS guidance?
The company raised its FY2024 adjusted diluted EPS guidance due to continued strong results, indicating positive operational performance in the current fiscal year.
What are the main reasons for projecting slower FY2025 growth?
Slower growth in FY2025 is primarily due to anticipated headwinds from declining COVID product demand (commercial vaccines) and the cessation of a significant COVID therapy contribution that benefited FY2024. A smaller impact comes from a potential customer loss due to an acquisition.
How significant is the Evernorth Health Services contract extension?
The extension of the pharmaceutical supply agreement with Evernorth Health Services for three additional years through September 2029 is a significant positive development. It ensures continued business with a major partner and provides revenue visibility for the medium term.
Will the potential loss of the oncology customer significantly impact Cencora's financials?
The filing states that the potential loss of the oncology customer is expected to have a lesser impact. While it's a factor being considered for FY2025 projections, it's not the primary driver of the moderated growth outlook.
04—Continue